Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

VEGF is a target molecule for peritoneal metastasis and malignant ascites in gastric cancer: prognostic significance of VEGF in ascites and efficacy of anti-VEGF monoclonal antibody.

Fushida S, Oyama K, Kinoshita J, Yagi Y, Okamoto K, Tajima H, Ninomiya I, Fujimura T, Ohta T.

Onco Targets Ther. 2013 Oct 16;6:1445-51. doi: 10.2147/OTT.S51916. eCollection 2013.

2.

Molecular targeting therapy using bevacizumab for peritoneal metastasis from gastric cancer.

Aoyagi K, Kouhuji K, Miyagi M, Kizaki J, Isobe T, Hashimoto K, Shirouzu K.

World J Crit Care Med. 2013 Nov 4;2(4):48-55. doi: 10.5492/wjccm.v2.i4.48. eCollection 2013 Nov 4.

3.

[The use of bevacizumab in refractory peritoneal dissemination of gastric cancer with malignant ascites-two case reports].

Kinoshita J, Fushida S, Makino I, Nakamura K, Oyama K, Nakagawara H, Fujita H, Tajima H, Takamura H, Ninomiya I, Kitagawa H, Tani T, Miyamoto M, Fujimura T, Ota T.

Gan To Kagaku Ryoho. 2011 Nov;38(12):2360-2. Japanese.

PMID:
22202382
4.

The clinical significance of vascular endothelial growth factor in malignant ascites.

Zhan N, Dong WG, Wang J.

Tumour Biol. 2016 Mar;37(3):3719-25. doi: 10.1007/s13277-015-4198-0. Epub 2015 Oct 13.

PMID:
26462841
5.

Biodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice.

Yagi Y, Fushida S, Harada S, Tsukada T, Kinoshita J, Oyama K, Fujita H, Ninomiya I, Fujimura T, Kayahara M, Kinuya S, Yashiro M, Hirakawa K, Ohta T.

Cancer Chemother Pharmacol. 2010 Sep;66(4):745-53. doi: 10.1007/s00280-009-1219-y. Epub 2009 Dec 24.

PMID:
20033809
6.

Gemcitabine suppresses malignant ascites of human pancreatic cancer: correlation with VEGF expression in ascites.

Kuwahara K, Sasaki T, Kobayashi K, Noma B, Serikawa M, Iiboshi T, Miyata H, Kuwada Y, Murakami M, Yamasaki S, Kariya K, Morinaka K, Chayama K.

Oncol Rep. 2004 Jan;11(1):73-80.

PMID:
14654905
7.

VEGF significance in peritoneal recurrence from gastric cancer.

Aoyagi K, Kouhuji K, Yano S, Miyagi M, Imaizumi T, Takeda J, Shirouzu K.

Gastric Cancer. 2005;8(3):155-63.

PMID:
16086118
8.
9.

Effect of bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor, on peritoneal metastasis of MNK-45P human gastric cancer in mice.

Ninomiya S, Inomata M, Tajima M, Ali AT, Ueda Y, Shiraishi N, Kitano S.

J Surg Res. 2009 Jun 15;154(2):196-202. doi: 10.1016/j.jss.2008.08.017. Epub 2008 Sep 16.

PMID:
19329124
10.

Expression of vascular endothelial growth factor and E-cadherin in human ovarian cancer: association with ascites fluid accumulation and peritoneal dissemination in mouse ascites model.

Akutagawa N, Nishikawa A, Iwasaki M, Fujimoto T, Teramoto M, Kitajima Y, Endo T, Shibuya M, Kudo R.

Jpn J Cancer Res. 2002 Jun;93(6):644-51.

PMID:
12079512
11.

Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease.

Kraft A, Weindel K, Ochs A, Marth C, Zmija J, Schumacher P, Unger C, Marmé D, Gastl G.

Cancer. 1999 Jan 1;85(1):178-87.

PMID:
9921991
12.

Suppressive effect of bevacizumab on peritoneal dissemination from gastric cancer in a peritoneal metastasis model.

Imaizumi T, Aoyagi K, Miyagi M, Shirouzu K.

Surg Today. 2010 Sep;40(9):851-7. doi: 10.1007/s00595-009-4154-y. Epub 2010 Aug 26.

PMID:
20740349
13.

Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up.

Rudlowski C, Pickart AK, Fuhljahn C, Friepoertner T, Schlehe B, Biesterfeld S, Schroeder W.

Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:183-9.

PMID:
16515588
14.

Differential expression of vascular endothelial growth factor-A, -C and -D for the diagnosis and prognosis of cancer patients with malignant effusions.

Jia L, DU Y, Li T, Lv Y, Wang Y, Zhang Y, Zhou X, Liu W.

Oncol Lett. 2015 Aug;10(2):667-674. Epub 2015 Jun 2.

15.

Intraperitoneal vascular endothelial growth factor burden in peritoneal surface malignancies treated with curative intent: the first step before intraperitoneal anti-vascular endothelial growth factor treatment?

Passot G, Bakrin N, Garnier L, Roux A, Vaudoyer D, Wallet F, Gilly FN, Glehen O, Cotte E.

Eur J Cancer. 2014 Mar;50(4):722-30. doi: 10.1016/j.ejca.2013.11.005. Epub 2013 Nov 29.

PMID:
24295636
16.

[Anti-VEGF therapy for peritoneal dissemination model of gastric cancer considering of pharmacokinetics].

Yagi Y, Fushida S, Fujita H, Kinami S, Ninomiya I, Fujimura T, Kayahara M, Ohta T, Yashiro M, Hirakawa K.

Gan To Kagaku Ryoho. 2008 Nov;35(12):2005-8. Japanese.

PMID:
19106505
17.

Markedly elevated levels of vascular endothelial growth factor in malignant ascites.

Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB, Ellis LM.

Ann Surg Oncol. 1999 Jun;6(4):373-8.

PMID:
10379858
18.

Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.

Yabushita H, Shimazu M, Noguchi M, Kishida T, Narumiya H, Sawaguchi K, Noguchi M.

Oncol Rep. 2003 Jan-Feb;10(1):89-95.

PMID:
12469150
19.

Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites?

Kobold S, Hegewisch-Becker S, Oechsle K, Jordan K, Bokemeyer C, Atanackovic D.

Oncologist. 2009 Dec;14(12):1242-51. doi: 10.1634/theoncologist.2009-0109. Epub 2009 Dec 11. Review.

20.

Role of VEGF and CD44v6 in differentiating benign from malignant ascites.

Dong WG, Sun XM, Yu BP, Luo HS, Yu JP.

World J Gastroenterol. 2003 Nov;9(11):2596-600.

Supplemental Content

Support Center